Journals / Literatür Eczacılık Bilimleri Dergisi / 2020 / Cilt: 9 - Sayı: 2

The Effect of Proton Pump Inhibitors on Possible Drug Interactions and Microbiota

Proton Pompası İnhibitörlerinin Olası İlaç Etkileşimleri ve Mikrobiyota Üzerine Etkileri

Pages
197–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, the effects of PPIs have been reviewed with the current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Proton pump inhibitors (PPIs) have been frequently used worldwide for the treatment of gastric acid related disorders long-term.
📊
Key Findings & Data:As PPIs indica- tions require long-term treatment, the likelihood of clinically significant drug interactions increases in patients using these drugs in combination with other drugs.
💡
Conclusion & Impact:In this article, the effects of PPIs have been reviewed with the current literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Proton pump inhibitors (PPIs) have been frequently used worldwide for the treatment of gastric acid related disorders long-term. It is currently preferred for gastroesophageal reflux, pep- tic ulcer and Zollinger-Ellison syndrome and the key to triple treat- ment of Helicobacter pylori eradication in patients with peptic ulcer. In addition, it is used prophylactically in stress and nonsteroidal anti- inflammatory drugs (NSAIDs) induced peptic ulcer. As PPIs indica- tions require long-term treatment, the likelihood of clinically significant drug interactions increases in patients using these drugs in combination with other drugs. Increasing the pH in the stomach is one of causative mechanism of the interaction of PPIs with other drugs. Another mechanism is the drug interactions that occur when the PPIs metabolized by the cytochrome p450 enzyme system in the liver are taken together with drugs that are bio-transformed with the same enzyme system. Gastric acid suppression by PPIs has a negative effect on bacterial composition in the small intestine. In addition to in- creased gastric pH by suppression of gastric acid by PPIs directly tar- geted bacteria and fungi proton pumps to affect the gastric microenvironment. The use of extended PPIs may result in the sup- pression of normal gastric flora and an excess of pathogenic bacte- ria. In this article, the effects of PPIs have been reviewed with the current literature.

Özet

Proton pompası inhibitörleri (PPİ), gastrik asit ilişkili rahatsız- lıkların tedavisi için uzun süreli olarak tüm dünyada sıklıkla kullanıl- maktadır. Günümüzde gastroözofageal reflü, peptik ülser ve Zollinger-Ellison sendromu tedavisinde tercih edilmekte olup, peptik ülser hastalarında Helicobacter pylori eradikasyonunda 3’lü tedavide anahtar rolündedir. Buna ek olarak, stres ve nonsteroidal antiinflama- tuar ilaç (NSAİİ)lar ile indüklenen peptik ülserde de proflaktik olarak kullanılmaktadır. PPİ’ler endikasyonu olan hastalıklar uzun süreli te- davi gerektirdiğinden, bu ilaçlarla birlikte diğer ilaçları kullanan has- talarda klinik olarak önemli ilaç etkileşimlerinin görülme olasılığı artmaktadır. PPİ’lerin midede pH’ı artırması, bu grup ilaçların diğer ilaçlarla etkileşimleri altındaki mekanizmalardan biridir. Bir diğer me- kanizma ise karaciğerde sitokrom P450 enzim sistemi ile metabolize olan PPİ’lerin, aynı enzim sistemi ile biyotransforme olan ilaçlarla bir- likte alınmaları durumunda oluşan ilaç etkileşimleridir. PPİ’ler tarafın- dan gastrik asit baskılanması, ince bağırsakta bakteri kompozisyonu üzerinde olumsuz etki göstermektedir. Mide asidinin baskılanmasıyla mide pH’ının artmasına ek olarak PPİ’ler, bakteri ve mantar proton pompalarını doğrudan hedef alarak mide mikro çevresini etkilemekte- dir. Genişletilmiş PPİ’lerin kullanımı normal gastrik floranın baskılan- masına ve patojenik bakteri fazlalığına yol açar. Sunulan bu çalışmada, PPİ’lerin etkisi güncel literatür bilgileri ile derlenmiştir.

🔖

Cite This Article

İSPİR, F. B., YÜCELİK, Ş. S. P., BAYDAR, T. (2020). The Effect of Proton Pump Inhibitors on Possible Drug Interactions and Microbiota. Literatür Eczacılık Bilimleri Dergisi, Cilt: 9 - Sayı: 2, 197–207. https://ajindex.com/articles/274566

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF. Drug-related prob- lems identification in general internal medi- cine: the impact and role of the clinical pharmacist and pharmacologist. Eur J Intern Med. 2015
  2. 26(6):399-406. [Crossref] [PubMed] 2. Marengoni A, Pasina L, Concoreggi C, Martini G, Brognoli F, Nobili A, et al. Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med. 2014
  3. 25(9):843-6. [Crossref] [PubMed] 3. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006
  4. 29(9):769-84. [Crossref] [PubMed] 4. Shih CJ, Chen YT, Ou SM, Li SY, Chen TJ, Wang SJ. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int J Cardiol. 2014
  5. 177(1):292-7. [Crossref] [PubMed] 5. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal in- jury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 2014
  6. 89(12):1699-709. [Crossref] [PubMed] 6. Wallace J, Paauw DS. Appropriate prescrib- ing and important drug interactions in older adults. Med Clin North Am. 2015
  7. 99(2):295- 310. [Crossref] [PubMed] 7. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itra- conazole. Eur J Clin Pharmacol. 1998
  8. 54(2):159-61. [Crossref] [PubMed] 8. Suzuki Y, Suzuki H, Umetsu R, Uranishi H, Abe J, Nishibata Y, et al. Analysis of the in- teraction between clopidogrel, aspirin, and proton pump inhibitors using the FDA Adverse Event Reporting System Database. Biol Pharm Bull. 2015
  9. 38(5):680-6. [Crossref] [PubMed] 9. Leonard CE, Bilker WB, Brensinger CM, Flockhart DA, Freeman CP, Kasner SE, et al. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke. 2015
  10. 46(3):722-31. [Crossref] [PubMed] [PMC] 10. Frelinger 3rd AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharma- codynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012
  11. 59(14):1304-11. [Crossref] [PubMed] 11. Nagata N, Niikura R, Aoki T, Sakurai T, Moriyasu S, Shimbo T, et al. Effect of proton- pump inhibitors on the risk of lower gastroin- testinal bleeding associated with NSAIDs, as